Panelists discuss how to overcome barriers to comprehensive molecular testing and how to prioritize treatment when ALK+ non–small cell lung cancer (NSCLC) coexists with other actionable biomarkers.
Molecular Testing and Biomarker Considerations
Key Themes:
Notable Insights:
Dr Lovly addressed treatment prioritization in patients with both ALK+ status and other biomarkers (eg, PD-L1 >1%)
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More